Financhill
Buy
57

VCYT Quote, Financials, Valuation and Earnings

Last price:
$29.03
Seasonality move :
22.55%
Day range:
$28.11 - $29.48
52-week range:
$19.73 - $47.32
Dividend yield:
0%
P/E ratio:
71.22x
P/S ratio:
4.98x
P/B ratio:
1.91x
Volume:
966.7K
Avg. volume:
1.1M
1-year change:
24.79%
Market cap:
$2.3B
Revenue:
$445.8M
EPS (TTM):
$0.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VCYT
Veracyte
$111M $0.20 6.44% 333.9% $40.50
APDN
Applied DNA Sciences
$1.2M -$3.00 27.47% -98.87% --
FONR
Fonar
-- -- -- -- --
OCX
OncoCyte
$126.8K -$0.25 180.72% -33.33% $4.42
PRPH
ProPhase Labs
$2.5M -$0.18 -32.58% -48.57% $13.80
XWEL
XWELL
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VCYT
Veracyte
$29.20 $40.50 $2.3B 71.22x $0.00 0% 4.98x
APDN
Applied DNA Sciences
$0.67 -- $739.5K -- $0.00 0% 0.04x
FONR
Fonar
$12.90 -- $81.7M 11.22x $0.00 0% 0.81x
OCX
OncoCyte
$2.79 $4.42 $79.8M -- $0.00 0% 12.65x
PRPH
ProPhase Labs
$0.39 $13.80 $16.2M -- $0.00 0% 1.17x
XWEL
XWELL
$0.91 -- $4.8M -- $0.00 0% 0.12x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VCYT
Veracyte
-- 3.551 -- 4.54x
APDN
Applied DNA Sciences
-- 5.301 -- 4.28x
FONR
Fonar
0.03% 1.233 0.07% 10.85x
OCX
OncoCyte
-- -1.798 -- 3.57x
PRPH
ProPhase Labs
31.06% -4.436 37.21% 1.12x
XWEL
XWELL
-- -0.848 -- 1.72x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VCYT
Veracyte
$79.5M $1.2M 2.85% 2.85% 1.02% $3.5M
APDN
Applied DNA Sciences
$684.1K -$3M -113.07% -113.07% -247.7% -$3.4M
FONR
Fonar
$9.7M $2.4M 4.95% 4.95% 11.92% $1.5M
OCX
OncoCyte
$1.3M -$5.9M -693.81% -693.81% -310.66% -$6.2M
PRPH
ProPhase Labs
-$165K -$7.9M -47.22% -59.59% -252.29% -$4.2M
XWEL
XWELL
$2.1M -$4.6M -71.82% -71.82% -54.82% -$3.8M

Veracyte vs. Competitors

  • Which has Higher Returns VCYT or APDN?

    Applied DNA Sciences has a net margin of 6.16% compared to Veracyte's net margin of -220.57%. Veracyte's return on equity of 2.85% beat Applied DNA Sciences's return on equity of -113.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
    APDN
    Applied DNA Sciences
    57.17% -$28.00 $12.5M
  • What do Analysts Say About VCYT or APDN?

    Veracyte has a consensus price target of $40.50, signalling upside risk potential of 38.7%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 223780.6%. Given that Applied DNA Sciences has higher upside potential than Veracyte, analysts believe Applied DNA Sciences is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    VCYT
    Veracyte
    7 2 1
    APDN
    Applied DNA Sciences
    0 1 0
  • Is VCYT or APDN More Risky?

    Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.491%.

  • Which is a Better Dividend Stock VCYT or APDN?

    Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VCYT or APDN?

    Veracyte quarterly revenues are $114.5M, which are larger than Applied DNA Sciences quarterly revenues of $1.2M. Veracyte's net income of $7M is higher than Applied DNA Sciences's net income of -$2.6M. Notably, Veracyte's price-to-earnings ratio is 71.22x while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.98x versus 0.04x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VCYT
    Veracyte
    4.98x 71.22x $114.5M $7M
    APDN
    Applied DNA Sciences
    0.04x -- $1.2M -$2.6M
  • Which has Higher Returns VCYT or FONR?

    Fonar has a net margin of 6.16% compared to Veracyte's net margin of 7.87%. Veracyte's return on equity of 2.85% beat Fonar's return on equity of 4.95%.

    Company Gross Margin Earnings Per Share Invested Capital
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
    FONR
    Fonar
    39.03% $0.29 $159M
  • What do Analysts Say About VCYT or FONR?

    Veracyte has a consensus price target of $40.50, signalling upside risk potential of 38.7%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    VCYT
    Veracyte
    7 2 1
    FONR
    Fonar
    0 0 0
  • Is VCYT or FONR More Risky?

    Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison Fonar has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.30600000000001%.

  • Which is a Better Dividend Stock VCYT or FONR?

    Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VCYT or FONR?

    Veracyte quarterly revenues are $114.5M, which are larger than Fonar quarterly revenues of $25M. Veracyte's net income of $7M is higher than Fonar's net income of $2M. Notably, Veracyte's price-to-earnings ratio is 71.22x while Fonar's PE ratio is 11.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.98x versus 0.81x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VCYT
    Veracyte
    4.98x 71.22x $114.5M $7M
    FONR
    Fonar
    0.81x 11.22x $25M $2M
  • Which has Higher Returns VCYT or OCX?

    OncoCyte has a net margin of 6.16% compared to Veracyte's net margin of -312.02%. Veracyte's return on equity of 2.85% beat OncoCyte's return on equity of -693.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
    OCX
    OncoCyte
    61.97% -$0.26 $10.2M
  • What do Analysts Say About VCYT or OCX?

    Veracyte has a consensus price target of $40.50, signalling upside risk potential of 38.7%. On the other hand OncoCyte has an analysts' consensus of $4.42 which suggests that it could grow by 58.3%. Given that OncoCyte has higher upside potential than Veracyte, analysts believe OncoCyte is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    VCYT
    Veracyte
    7 2 1
    OCX
    OncoCyte
    1 2 0
  • Is VCYT or OCX More Risky?

    Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison OncoCyte has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.749%.

  • Which is a Better Dividend Stock VCYT or OCX?

    Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VCYT or OCX?

    Veracyte quarterly revenues are $114.5M, which are larger than OncoCyte quarterly revenues of $2.1M. Veracyte's net income of $7M is higher than OncoCyte's net income of -$6.7M. Notably, Veracyte's price-to-earnings ratio is 71.22x while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.98x versus 12.65x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VCYT
    Veracyte
    4.98x 71.22x $114.5M $7M
    OCX
    OncoCyte
    12.65x -- $2.1M -$6.7M
  • Which has Higher Returns VCYT or PRPH?

    ProPhase Labs has a net margin of 6.16% compared to Veracyte's net margin of -209.38%. Veracyte's return on equity of 2.85% beat ProPhase Labs's return on equity of -59.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
  • What do Analysts Say About VCYT or PRPH?

    Veracyte has a consensus price target of $40.50, signalling upside risk potential of 38.7%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3465.89%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    VCYT
    Veracyte
    7 2 1
    PRPH
    ProPhase Labs
    0 0 0
  • Is VCYT or PRPH More Risky?

    Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.472, suggesting its less volatile than the S&P 500 by 147.175%.

  • Which is a Better Dividend Stock VCYT or PRPH?

    Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VCYT or PRPH?

    Veracyte quarterly revenues are $114.5M, which are larger than ProPhase Labs quarterly revenues of $3.1M. Veracyte's net income of $7M is higher than ProPhase Labs's net income of -$6.6M. Notably, Veracyte's price-to-earnings ratio is 71.22x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.98x versus 1.17x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VCYT
    Veracyte
    4.98x 71.22x $114.5M $7M
    PRPH
    ProPhase Labs
    1.17x -- $3.1M -$6.6M
  • Which has Higher Returns VCYT or XWEL?

    XWELL has a net margin of 6.16% compared to Veracyte's net margin of -56.4%. Veracyte's return on equity of 2.85% beat XWELL's return on equity of -71.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
    XWEL
    XWELL
    24.38% -$0.99 $14.8M
  • What do Analysts Say About VCYT or XWEL?

    Veracyte has a consensus price target of $40.50, signalling upside risk potential of 38.7%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 669.23%. Given that XWELL has higher upside potential than Veracyte, analysts believe XWELL is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    VCYT
    Veracyte
    7 2 1
    XWEL
    XWELL
    0 0 0
  • Is VCYT or XWEL More Risky?

    Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

  • Which is a Better Dividend Stock VCYT or XWEL?

    Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VCYT or XWEL?

    Veracyte quarterly revenues are $114.5M, which are larger than XWELL quarterly revenues of $8.4M. Veracyte's net income of $7M is higher than XWELL's net income of -$4.8M. Notably, Veracyte's price-to-earnings ratio is 71.22x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.98x versus 0.12x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VCYT
    Veracyte
    4.98x 71.22x $114.5M $7M
    XWEL
    XWELL
    0.12x -- $8.4M -$4.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Ginkgo Bioworks Stock a Good Buy?
Is Ginkgo Bioworks Stock a Good Buy?

Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…

Why Mobileye Might Be Wall Street’s Next Big Surprise
Why Mobileye Might Be Wall Street’s Next Big Surprise

The trend to automate vehicles started long ago when adding…

Why Is Rigetti Stock Going Up?
Why Is Rigetti Stock Going Up?

Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
81
SMLR alert for May 19

Semler Scientific [SMLR] is up 5.85% over the past day.

Sell
25
GLOB alert for May 19

Globant SA [GLOB] is up 4.02% over the past day.

Buy
94
HIMS alert for May 19

Hims & Hers Health [HIMS] is down 3.57% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock